Transdermal cannabinoids ease neuropathic pain significantly

Transdermal cannabinoids offer relief for diabetic neuropathy

In a groundbreaking study conducted in Khon Kaen, Thailand, researchers have revealed that transdermal formulations of plant-derived cannabinoids can significantly reduce symptoms of diabetic neuropathy.

The trial, which was published in Medical Cannabis and Cannabinoids, involved the application of cannabinoid oils on patients diagnosed with diabetic peripheral neuropathy (DPN) in their lower extremities.

The clinical trial and its promising results

The Phase III trial enrolled 100 participants with painful diabetic neuropathy. These individuals were divided into two groups: one received the cannabinoid-based transdermal formula, while the other used a placebo (coconut oil).

The cannabinoid formulation contained specific concentrations of THC (3.20 mg/drop), CBD (0.32 mg/drop), and CBN (0.65 mg/drop). Over 12 weeks, the researchers assessed participants’ pain levels using the Neuropathic Pain Symptom Inventory (NPSI-T).

The results were striking. Patients in the treatment group experienced a marked reduction in pain scores, with their mean scores dropping from 25.60 to 5.57. In contrast, the placebo group saw a much smaller decrease, from 25.24 to 22.85.

This dramatic improvement was consistent across all assessment points at four, eight, and 12 weeks.

Safety profile and patient experiences

The study also highlighted the excellent safety profile of the cannabinoid formulation. Only 10% of participants reported mild adverse events, which were similar in frequency to those observed in the placebo group. This finding underscores the potential of cannabinoids as a safe option for managing neuropathic pain.

Implications for cannabinoid-based pain relief

While previous studies have demonstrated the effectiveness of various cannabis formulations in managing neuropathic pain, including vaporized and aerosolized cannabinoids, this trial focuses on the unique benefits of transdermal application.

The findings suggest that transdermal cannabinoids could become a viable option for individuals seeking alternative methods to manage chronic pain.

Personal perspective

I find these results particularly encouraging. The use of plant-derived cannabinoids, especially in a non-invasive form like transdermal application, presents a significant advancement in pain management.

It offers hope to countless individuals grappling with the debilitating effects of diabetic neuropathy. Moreover, the safety profile shown in this study adds a layer of reassurance for potential users.

While more research is necessary to explore the long-term effects and scalability of such treatments, this study underscores the growing role of cannabinoids in addressing pain-related conditions. For patients and practitioners alike, this innovative approach holds immense promise.